Moreover, our group has reported the pivotal role of MAPK15 and NF-κB signaling in boosting the efficacy of combination therapy with cisplatin and TNF-α, as well as increasing arsenic trioxide-induced cell apoptosis, in lung cancer cell lines [14,15]. The gene discussed is NFKB1; the disease is lung cancer.